Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data: comment from Berkowitz et al

MeSH terms

• Adverse Drug Reaction Reporting Systems*
• Antibodies, Bispecific* / adverse effects
• Antibodies, Bispecific* / therapeutic use
• Antibodies, Monoclonal, Humanized* / adverse effects
• Antibodies, Monoclonal, Humanized* / therapeutic use
• Factor VIII* / adverse effects
• Hemophilia A / blood
• Hemophilia A / diagnosis
• Hemophilia A / drug therapy
• Humans
• Risk Factors
• Thrombosis* / chemically induced
• Thrombosis* / epidemiology
• Thrombosis* / prevention & control
• United States / epidemiology
• United States Food and Drug Administration